JP2022506110A5 - - Google Patents
Info
- Publication number
- JP2022506110A5 JP2022506110A5 JP2021523278A JP2021523278A JP2022506110A5 JP 2022506110 A5 JP2022506110 A5 JP 2022506110A5 JP 2021523278 A JP2021523278 A JP 2021523278A JP 2021523278 A JP2021523278 A JP 2021523278A JP 2022506110 A5 JP2022506110 A5 JP 2022506110A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- solvate
- hydrate
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185222A JP2025011310A (ja) | 2018-10-30 | 2024-10-21 | 治療用化合物および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752503P | 2018-10-30 | 2018-10-30 | |
| US62/752,503 | 2018-10-30 | ||
| PCT/US2019/058896 WO2020092592A1 (en) | 2018-10-30 | 2019-10-30 | Therapeutic compounds and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185222A Division JP2025011310A (ja) | 2018-10-30 | 2024-10-21 | 治療用化合物および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506110A JP2022506110A (ja) | 2022-01-17 |
| JP2022506110A5 true JP2022506110A5 (cg-RX-API-DMAC10.html) | 2022-10-28 |
Family
ID=70464752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523278A Pending JP2022506110A (ja) | 2018-10-30 | 2019-10-30 | 治療用化合物および組成物 |
| JP2024185222A Pending JP2025011310A (ja) | 2018-10-30 | 2024-10-21 | 治療用化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185222A Pending JP2025011310A (ja) | 2018-10-30 | 2024-10-21 | 治療用化合物および組成物 |
Country Status (10)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499532B2 (en) | 2014-02-07 | 2016-11-22 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| WO2019156929A1 (en) | 2018-02-07 | 2019-08-15 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| CA3117549A1 (en) * | 2018-10-30 | 2020-05-07 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| EP4213857A4 (en) * | 2020-09-17 | 2024-11-20 | Exithera Pharmaceuticals Inc. | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF |
| CN116782911A (zh) * | 2020-09-17 | 2023-09-19 | 艾克赛特赫拉制药有限责任公司 | 治疗性化合物、组合物及其使用方法 |
| TW202346278A (zh) * | 2022-03-28 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 2-氨基吡啶衍生物製備方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9802206D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| CA2648522A1 (en) * | 2005-04-04 | 2006-10-12 | Daiamed, Inc. | Substituted azetidinones |
| JP5385895B2 (ja) * | 2007-04-10 | 2014-01-08 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なチアゾリル化合物 |
| LT2766346T (lt) * | 2011-10-14 | 2017-06-12 | Bristol-Myers Squibb Company | Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai |
| US9499532B2 (en) * | 2014-02-07 | 2016-11-22 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| US20190315711A1 (en) * | 2016-12-23 | 2019-10-17 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
-
2019
- 2019-10-30 CA CA3117470A patent/CA3117470A1/en active Pending
- 2019-10-30 AU AU2019373237A patent/AU2019373237A1/en not_active Abandoned
- 2019-10-30 BR BR112021008345-6A patent/BR112021008345A2/pt unknown
- 2019-10-30 KR KR1020217014647A patent/KR20210087467A/ko not_active Withdrawn
- 2019-10-30 EP EP19877575.1A patent/EP3873444A4/en active Pending
- 2019-10-30 WO PCT/US2019/058896 patent/WO2020092592A1/en not_active Ceased
- 2019-10-30 JP JP2021523278A patent/JP2022506110A/ja active Pending
- 2019-10-30 CN CN201980072037.6A patent/CN112996495A/zh active Pending
-
2021
- 2021-04-28 IL IL282766A patent/IL282766A/en unknown
- 2021-04-28 US US17/243,120 patent/US20210261524A1/en not_active Abandoned
-
2024
- 2024-10-21 JP JP2024185222A patent/JP2025011310A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gimson et al. | Earlier charcoal haemoperfusion in fulminant hepatic failure | |
| JP2022523712A5 (cg-RX-API-DMAC10.html) | ||
| JP2022506109A5 (cg-RX-API-DMAC10.html) | ||
| Nicolau et al. | Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis | |
| Buchanan | Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure | |
| Heney et al. | Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome | |
| Ponikvar et al. | Use of prostacyclin as the only anticoagulant during continuous venovenous hemofiltration | |
| Schmidt et al. | Studies on the neurotoxicity of ethambutol and its racemate for the rhesus monkey | |
| Heath et al. | Treatment of antidepressant poisoning with resin hemoperfusion | |
| Gaynor | Use of modified ultrafiltration after repair of congenital heart defects | |
| RU2021115308A (ru) | Терапевтические соединения и композиции | |
| JP2006502231A5 (cg-RX-API-DMAC10.html) | ||
| Clar et al. | Hemofiltration: determinants of drug loss and concentration | |
| Dorsey | Venoarterial bypass in hypothermia | |
| CN102205115B (zh) | 乌司他丁作为急腹症引起的中毒性休克的抢救辅助药物的用途 | |
| RU2021115313A (ru) | Терапевтические соединения и композиция | |
| Caruso et al. | Continuous hemodialysis for the management of acute renal failure in the presence of cerebellar hemorrhage: case report | |
| WO1996037205A1 (en) | Remedy for endotoxinemia and multiple organ failure induced thereby | |
| Balazs et al. | Comparison of effects of quinidine and dihydroquinidine on canine heart | |
| Kawahito et al. | Pathophysiology and complications during extracorporeal circulation | |
| Crerar-Gilbert et al. | Use of inhaled nitric oxide in pulmonary embolism | |
| Heath et al. | Resin hemoperfusion in chloroquine poisoning | |
| Marshall | Tricyclic overdose | |
| Fanous et al. | Severe anaphylactoid reactions to dextran 70 | |
| US3632765A (en) | Treatment of shock |